Lymphangiogenesis and cancer metastasis

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 A, 2009, Pages 1405-1416

  Mumprecht, Viviane ^a   Detmar, Michael ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Cancer metastasis; Cancer metastasis prediction and prevention; Imaging of lymphatic vessels; Lymphangiogenesis

Indexed keywords

TUMOR MARKER;

ANIMAL; ARTICLE; CANCER INVASION; DIAGNOSTIC IMAGING; HUMAN; LYMPH VESSEL; LYMPHANGIOGENESIS; METABOLISM; METASTASIS; PATHOLOGY;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349330902     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00834.x     Document Type: Article

References (148)

1. Cueni LN, Detmar M. The lymphatic system in health and disease. Lymphat Res Biol. 2008 6 : 109 122.
2. Gerli R, Solito R, Weber E, et al. Specific adhesion molecules bind anchoring filaments and endothelial cells in human skin initial lymphatics. Lymphology. 2000 33 : 148 157.
3. Baluk P, Fuxe J, Hashizume H, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med. 2007 204 : 2349 2362.
4. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001 20 : 672 682. (Pubitemid 32167632)
5. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001 7 : 192 198.
6. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001 7 : 186 191.
7. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005 201 : 1089 1099.
8. Hirakawa S, Brown LF, Kodama S, et al. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood. 2007 109 : 1010 1017.
9. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 2008 216 : 347 354.
10. Van Der Auwera I, Cao Y, Tille JC, et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer. 2006 95 : 1611 1625.
11. Pepper MS, Tille JC, Nisato R, et al. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003 314 : 167 177. (Pubitemid 37409922)
12. Rinderknecht M, Detmar M. Lymphangiogenesis in cancer metastasis. In : Stacker SA, Achen MG, editors. Cancer metastasis - biology and treatment. 2009. Berlin : Springer, Science+Business Media B.V. in press.
13. He Y, Rajantie I, Pajusola K, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005 65 : 4739 4746.
14. Nathanson SD, Anaya P, Avery M, et al. Sentinel lymph node metastasis in experimental melanoma: relationships among primary tumor size, lymphatic vessel diameter and 99mTc-labeled human serum albumin clearance. Ann Surg Oncol. 1997 4 : 161 168.
15. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003 162 : 1951 1960.
16. Franchi A, Gallo O, Massi D, et al. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer. 2004 101 : 973 978.
17. Van Der Auwera I, Van Den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res. 2005 11 : 7637 7642.
18. Liang P, Hong JW, Ubukata H, et al. Increased density and diameter of lymphatic microvessels correlate with lymph node metastasis in early stage invasive colorectal carcinoma. Virchows Arch. 2006 448 : 570 575.
19. Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol. 2006 59 : 166 173.
20. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol. 2001 159 : 893 903.
21. He Y, Rajantie I, Ilmonen M, et al. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 2004 64 : 3737 3740.
22. Religa P, Cao R, Bjorndahl M, et al. Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood. 2005 106 : 4184 4190.
23. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005 115 : 2363 2372.
24. Kerjaschki D, Huttary N, Raab I, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006 12 : 230 234.
25. Qian CN, Berghuis B, Tsarfaty G, et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 2006 66 : 10365 10376.
26. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol. 2007 170 : 774 786.
27. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005 18 : 1232 1242.
28. Van Den Eynden GG, Vandenberghe MK, van Dam PJ, et al. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin Cancer Res. 2007 13 : 5391 5397.
29. Kerjaschki D, Regele HM, Moosberger I, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004 15 : 603 612.
30. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001 410 : 50 6.
31. Shields JD, Emmett MS, Dunn DB, et al. Chemokine-mediated migration of melanoma cells towards lymphatics - a mechanism contributing to metastasis. Oncogene. 2006 26 : 2997 3005.
32. Wiley HE, Gonzalez EB, Maki W, et al. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001 93 : 1638 1643.
33. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002 296 : 1883 1886.
34. Wong SY, Haack H, Crowley D, et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005 65 : 9789 9798.
35. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 2002 62 : 1315 1320.
36. Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 2003 63 : 1920 1926.
37. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999 98 : 769 778.
38. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 2002 16 : 773 783.
39. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999 144 : 789 801.
40. Jackson DG, Prevo R, Clasper S, et al. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 2001 22 : 317 321.
41. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999 154 : 385 394.
42. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA. 1995 92 : 3566 3570.
43. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002 21 : 1505 1513. (Pubitemid 34614607)
44. Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet. 2004 36 : 683 685.
45. Srinivasan RS, Dillard ME, Lagutin OV, et al. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 2007 21 : 2422 2432.
46. Gale NW, Prevo R, Espinosa J, et al. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol Cell Biol. 2007 27 : 595 604.
47. Nightingale TD, Frayne ME, Clasper S, et al. A mechanism of sialylation functionally silences the hyaluronan receptor LYVE-1 in lymphatic endothelium. J Biol Chem. 2009 284 : 3935 3945.
48. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005 166 : 913 921.
49. Martin-Villar E, Scholl FG, Gamallo C, et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer. 2005 113 : 899 910.
50. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroen-docrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 2000 14 : 2087 2096.
51. Jurisic G, Detmar M. Lymphatic endothelium in health and disease. Cell Tissue Res. 2009 335 : 97 108.
52. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol. 2003 162 : 575 586.
53. Roesli C, Mumprecht V, Neri D, Detmar M. Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J. 2008 22 : 1933 1944.
54. Shin JW, Huggenberger R, Detmar M. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood. 2008 112 : 2318 2326.
55. Clasper S, Royston D, Baban D, et al. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res. 2008 68 : 7293 7303.
56. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996 15 : 290 298.
57. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998 95 : 548 553.
58. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002 196 : 1497 1506.
59. Kajiya K, Hirakawa S, Ma B, et al. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005 24 : 2885 2895.
60. Morisada T, Oike Y, Yamada Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 2005 105 : 4649 4656. (Pubitemid 40807284)
61. Tammela T, Saaristo A, Lohela M, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood. 2005 105 : 4642 4648.
62. Kubo H, Cao R, Brakenhielm E, et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibrob-last growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA. 2002 99 : 8868 8873.
63. Shin JW, Min M, Larrieu-Lahargue F, et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphan-giogenesis. Mol Biol Cell. 2006 17 : 576 584.
64. Bjorndahl M, Cao R, Nissen LJ, et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA. 2005 102 : 15593 15598.
65. Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004 6 : 333 345.
66. Fritz-Six KL, Dunworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest. 2008 118 : 40 50.
67. Banziger-Tobler NE, Halin C, Kajiya K, Detmar M. Growth hormone promotes lymphangiogenesis. Am J Pathol. 2008 173 : 586 597.
68. Spinella F, Garrafa E, Di Castro V, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 2009 69 : 2669 2676.
69. Clavin NW, Avraham T, Fernandez J, et al. TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am J Physiol Heart Circ Physiol. 2008 295 : H2113 27.
70. Iwata C, Kano MR, Komuro A, et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 2007 67 : 10181 10189.
71. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002 161 : 947 956.
72. Angeli V, Ginhoux F, Llodra J, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity. 2006 24 : 203 215.
73. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005 115 : 247 257.
74. Red-Horse K, Rivera J, Schanz A, et al. Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation. J Clin Invest. 2006 116 : 2643 2652.
75. Proulx ST, Kwok E, You Z, et al. Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum. 2007 56 : 4024 4037.
76. Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006 66 : 2650 2657.
77. Shimizu K, Kubo H, Yamaguchi K, et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 2004 95 : 328 333.
78. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005 65 : 6901 6909.
79. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002 94 : 819 825.
80. Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 2003 63 : 713 722.
81. He XW, Liu T, Chen YX, et al. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther. 2008 15 : 193 202.
82. Chen Z, Varney ML, Backora MW, et al. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 2005 65 : 9004 9011.
83. Caunt M, Mak J, Liang WC, et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell. 2008 13 : 331 342.
84. Favier B, Alam A, Barron P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 2006 108 : 1243 1250.
85. Yuan L, Moyon D, Pardanaud L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development. 2002 129 : 4797 4806.
86. Karpanen T, Wirzenius M, Makinen T, et al. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol. 2006 169 : 708 718.
87. Dietrich T, Onderka J, Bock F, et al. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am J Pathol. 2007 171 : 361 372.
88. Hong YK, Lange-Asschenfeldt B, Velasco P, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004 18 : 1111 1113.
89. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer. 2003 98 : 413 423.
90. Dadras SS, Detmar M. Angiogenesis and lymphangiogenesis of skin cancers. Hematol Oncol Clin North Am. 2004 18 : 1059 1070.
91. Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg. 2003 138 : 482 487 discussion 7-8.
92. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007 25 : 3657 3663.
93. Campbell SC, Klein EA, Levin HS, Piedmonte MR. Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology. 1995 46 : 352 355.
94. Sharma R, Wendt JA, Rasmussen JC, et al. New horizons for imaging lymphatic function. Ann N Y Acad Sci. 2008 1131 : 13 36.
95. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004 240 : 306 312.
96. Lee AH, Pinder SE, Macmillan RD, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer. 2006 42 : 357 362.
97. Doeden K, Ma Z, Narasimhan B, et al. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol. 2009 36 : 772 780.
98. Hyung WJ, Lee JH, Choi SH, et al. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol. 2002 9 : 562 567.
99. Kooby DA, Suriawinata A, Klimstra DS, et al. Biologic predictors of survival in node-negative gastric cancer. Ann Surg. 2003 237 : 828 835 discussion 35-7.
100. Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg. 2006 243 : 64 73.
101. Arigami T, Natsugoe S, Uenosono Y, et al. Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer. 2005 93 : 688 693.
102. Vazquez-Sequeiros E, Wang L, Burgart L, et al. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology. 2002 122 : 1815 1821.
103. Lotan Y, Gupta A, Shariat SF, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005 23 : 6533 6539.
104. Goydos JS, Gorski DH. Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin Cancer Res. 2003 9 : 5962 5967.
105. Mathur SP, Mathur RS, Gray EA, et al. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol. 2005 98 : 467 483.
106. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett. 2007 249 : 171 177.
107. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer. 2003 98 : 1217 1222.
108. Vihinen P P, Hilli J, Vuoristo MS, et al. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol. 2007 46 : 678 684.
109. Duff SE, Li C, Renehan A, et al. Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int J Oncol. 2003 22 : 339 343.
110. Strauss L, Volland D, Kunkel M, Reichert TE. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogen-esis and immune tolerance. Med Sci Monit. 2005 11 : BR280 92.
111. Duff SE, Saunders M, McCredie V, et al. Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. Clin Oncol (R Coll Radiol). 2005 17 : 367 371.
112. Hoar FJ, Lip GY, Belgore F, et al. Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer. Int J Biol Markers. 2004 19 : 229 235.
113. Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer. 2005 103 : 724 730.
114. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res. 2003 9 : 5313 5317.
115. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol. 2005 18 : 143 152.
116. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat. 2005 91 : 125 132.
117. Li YS, Kaneko M, Amatya VJ, et al. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast. Pathol Int. 2006 56 : 256 261.
118. Gombos Z, Xu X, Chu CS, et al. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res. 2005 11 : 8364 8371.
119. Kurahara H, Takao S, Maemura K, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res. 2004 10 : 8413 8420.
120. Onogawa S, Kitadai Y, Tanaka S, et al. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004 95 : 32 9.
121. Shintani S, Li C, Ishikawa T, et al. Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol. 2004 40 : 13 20. (Pubitemid 37510207)
122. Zhang B, Zhao WH, Zhou WY, et al. Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma. Cancer Detect Prev. 2007 31 : 436 442.
123. Ruddell A, Harrell MI, Minoshima S, et al. Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow. Neoplasia. 2008 10 : 706 713.
124. Ji RC. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol. 2009 24 : 377 384.
125. Kajiya K, Hirakawa S, Detmar M. Vascular endothelial growth factor-a mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol. 2006 169 : 1496 1503.
126. Mellor RH, Stanton AW, Azarbod P, et al. Enhanced cutaneous lymphatic network in the forearms of women with postmastec-tomy oedema. J Vasc Res. 2000 37 : 501 512.
127. Kobayashi H, Kawamoto S, Brechbiel MW, et al. Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphan-giography with a gadolinum-labeled dendrimer nanoparticle. Neoplasia. 2005 7 : 984 991.
128. Kobayashi H, Kawamoto S, Sakai Y, et al. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst. 2004 96 : 703 708.
129. Barrett T, Choyke PL, Kobayashi H. Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging. 2006 1 : 230 245.
130. Sharma R, Wang W, Rasmussen JC, et al. Quantitative imaging of lymph function. Am J Physiol Heart Circ Physiol. 2007 292 : H3109 18.
131. Unno N, Inuzuka K, Suzuki M, et al. Preliminary experience with a novel fluorescence lymphography using indocyanine green in patients with secondary lymphedema. J Vasc Surg. 2007 45 : 1016 1021.
132. Sevick-Muraca EM, Sharma R, Rasmussen JC, et al. Imaging of lymph flow in breast cancer patients after micro-dose administration of a near-infrared fluorophore: feasibility study. Radiology. 2008 246 : 734 741.
133. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer - a multi-center validation study. N Engl J Med. 1998 339 : 941 946. (Pubitemid 28455095)
134. Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol. 2004 22 : 93 7.
135. Ballou B, Ernst LA, Andreko S, et al. Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug Chem. 2007 18 : 389 396.
136. Hama Y, Koyama Y, Bernardo M, et al. Spectral near-infrared fluorescence imaging of curved surfaces using projection reconstruction algorithms. Contrast Media Mol Imaging. 2007 2 : 82 7.
137. Kobayashi H, Hama Y, Koyama Y, et al. Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett. 2007 7 : 1711 1716.
138. Hama Y, Koyama Y, Urano Y, et al. Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res Treat. 2007 103 : 23 8.
139. Kitai T, Inomoto T, Miwa M, et al. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005 12 : 211 215.
140. Proulx ST, Kwok E, You Z, et al. MRI and quantification of draining lymph node function in inflammatory arthritis. Ann N Y Acad Sci. 2007 1117 : 106 123.
141. Motomura K, Inaji H, Komoike Y, et al. Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol. 2001 27 : 141 145.
142. Bedrosian I, Bedi D, Kuerer HM, et al. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 10 : 1025 1030.
143. Choi SH, Kono Y, Corbeil J, et al. Model to quantify lymph node enhancement on indirect sonographic lymphography. AJR Am J Roentgenol. 2004 183 : 513 517.
144. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007 244 : 39 47.
145. Cserni G. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol. 1999 52 : 922 924. (Pubitemid 30005368)
146. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. Jama. 2005 293 : 855 862.
147. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003 348 : 2491 2499. (Pubitemid 36706536)
148. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept. 2003 112 : 175 183.